| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRTX | Common Stock | Award | $0 | +8.17K | +24.31% | $0.00 | 41.8K | Feb 1, 2022 | Direct | F1 |
| transaction | VRTX | Common Stock | Award | $0 | +11.6K | +27.85% | $0.00 | 53.4K | Feb 1, 2022 | Direct | F2 |
| transaction | VRTX | Common Stock | Award | $0 | +12.3K | +23.07% | $0.00 | 65.7K | Feb 1, 2022 | Direct | F3 |
| transaction | VRTX | Common Stock | Options Exercise | $403K | +4.66K | +7.09% | $86.52* | 70.4K | Feb 2, 2022 | Direct | |
| transaction | VRTX | Common Stock | Sale | -$124K | -500 | -0.71% | $247.73 | 69.9K | Feb 2, 2022 | Direct | F4, F5, F6 |
| transaction | VRTX | Common Stock | Sale | -$31.6K | -127 | -0.18% | $248.65 | 69.7K | Feb 2, 2022 | Direct | F4, F6, F7 |
| transaction | VRTX | Common Stock | Sale | -$188K | -754 | -1.08% | $249.97 | 69K | Feb 2, 2022 | Direct | F4, F6, F8 |
| transaction | VRTX | Common Stock | Sale | -$246K | -980 | -1.42% | $251.22 | 68K | Feb 2, 2022 | Direct | F4, F6, F9 |
| transaction | VRTX | Common Stock | Sale | -$227K | -900 | -1.32% | $252.10 | 67.1K | Feb 2, 2022 | Direct | F4, F6, F10 |
| transaction | VRTX | Common Stock | Sale | -$278K | -1.1K | -1.64% | $253.41 | 66K | Feb 2, 2022 | Direct | F4, F6, F11 |
| transaction | VRTX | Common Stock | Sale | -$76.3K | -300 | -0.45% | $254.46 | 65.7K | Feb 2, 2022 | Direct | F4, F6, F12 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | VRTX | Stock Option (Right to Buy) | Options Exercise | -$403K | -4.66K | -100% | $86.52* | 0 | Feb 2, 2022 | Common Stock | 4.66K | $86.52 | Direct | F13 |
| Id | Content |
|---|---|
| F1 | Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022. |
| F2 | Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022. |
| F3 | Restricted stock unit award that vests in installments beginning on 02/24/2023. |
| F4 | Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. |
| F5 | Open market sales reported on this line occurred at a weighted average price of $247.73 (range $247.35 to $248.34). |
| F6 | Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| F7 | Open market sales reported on this line occurred at a weighted average price of $248.65 (range $248.46 to $249.34). |
| F8 | Open market sales reported on this line occurred at a weighted average price of $249.97 (range $249.61 to $250.33). |
| F9 | Open market sales reported on this line occurred at a weighted average price of $251.22 (range $250.71 to $251.70). |
| F10 | Open market sales reported on this line occurred at a weighted average price of $252.10 (range $251.75 to $252.72). |
| F11 | Open market sales reported on this line occurred at a weighted average price of $253.41 (range $253.05 to $253.99). |
| F12 | Open market sales reported on this line occurred at a weighted average price of $254.46 (range $254.34 to $254.58). |
| F13 | Fully vested. |
Exhibit 24 - Power of Attorney